Skip Navigation

JNCI Journal of the National Cancer Institute 1996 88(22):1652-1658; doi:10.1093/jnci/88.22.1652
© 1996 by Oxford University Press
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Diel, I. J.
Right arrow Articles by Bastert, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Diel, I. J.
Right arrow Articles by Bastert, G.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 88, No. 22, 1652-1658, November 20, 1996
© 1996 Oxford University Press

Micrometastatic Breast Cancer Cells in Bone Marrow at Primary Surgery: Prognostic Value in Comparison With Nodal Status

Ingo J. Diel, Manfred Kaufmann, Serban D. Costa, Rolf Holle, Gunter von Minckwitz, Erich F. Solomayer, Sepp Kaul, Gunther Bastert

Department of Obstetrics and Gynecology, University of Heidelberg Federal Republic of Germany
Department of Medical Biometry, University of Heidelberg Federal Republic of Germany

Correspondence to: Ingo J. Diel, M.D., Department of Obstetrics and Gynecology, University Hospital, Voss-Strasse 9, 69115 Heidelberg, Federal Republic of Germany.

BACKGROUND:: Approximately 30% of the patients with primary breast cancer who have no axillary lymph node involvement (i.e., lymph node negative) at the time of surgery will relapse within 10 years; 10%–20% of the patients with distant metastases will be lymph node negative at surgery. Axillary lymph node dissection, as a surgical procedure, is associated with frequent complications. A possible alternative to nodal dissection in terms of prognosis may be the immunocytochemical detection of tumor cells in bone marrow.

PURPOSE:: In a prospective study, the value of tumor cell detection (TCD) in bone marrow was compared with axillary lymph node dissection in the prognosis of primary breast cancer after surgery.

METHODS:: Data from 727 patients with primary, operable breast cancer were included in the analysis. All patients had surgery, including axillary lymph node dissection, from May 1985 through July 1994 at the Women's Hospital of the University of Heidelberg (Federal Republic of Germany). Bone marrow aspiration at two sites on each anterior iliac crest was performed immediately after surgery while the patients were under general anesthesia. Most patients received some type of systemic adjuvant therapy. The monoclonal antibody 2E11, directed against the polymorphic epithelial mucin TAG12, was used to detect tumor cells in bone marrow samples. The association of TCD with recognized prognostic indicators was evaluated by means of chi-squared tests. Survival without the development of distant metastases (i.e., distant disease-free survival) and overall survival were estimated by use of the Kaplan-Meier method; the logrank test was used to compare survival curves. A multivariate Cox regression analysis with stratification according to adjuvant treatment type was used to assess the independent prognostic value of TCD in bone marrow in relation to other variables. Reported P values are two-sided. Results: Tumor cells were detected in the bone marrow of 203 (55%) of 367 lymph node-positive patients and in 112 (31%) of 360 lymph node-negative patients. TCD was associated with larger tumors (P<.001), lymph node involvement (P = .001), and higher tumor grade (i.e., more undifferentiated) (P = .002). After a median follow-up of 36 months, patients with tumor cells in their bone marrow experienced reduced distant disease-free survival and overall survival (both P values <.001). TCD was an independent prognostic indicator for both distant disease-free survival and overall survival that was superior to axillary lymph node status, tumor stage, and tumor grade. Among patients with tumors less than 2 cm in diameter, TCD was the most powerful predictor of outcome.

CONCLUSIONS AND IMPLICATIONS:: TCD in the bone marrow of patients with breast cancer is a valuable prognostic tool associated with negligible morbidity. Prospective randomized studies should be performed to determine whether TCD might replace axillary lymph node dissection in a defined subgroup of patients with small tumors.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Ann OncolHome page
I. J. Diel, A. Jaschke, E. F. Solomayer, C. Gollan, G. Bastert, C. Sohn, and F. Schuetz
Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow--a long-term follow-up
Ann. Onc., December 1, 2008; 19(12): 2007 - 2011.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
A Vincent-Salomon, F C Bidard, and J Y Pierga
Bone marrow micrometastasis in breast cancer: review of detection methods, prognostic impact and biological issues
J. Clin. Pathol., May 1, 2008; 61(5): 570 - 576.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
L. Harris, H. Fritsche, R. Mennel, L. Norton, P. Ravdin, S. Taube, M. R. Somerfield, D. F. Hayes, and R. C. Bast Jr
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
J. Clin. Oncol., November 20, 2007; 25(33): 5287 - 5312.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
N. Xenidis, V. Markos, S. Apostolaki, M. Perraki, A. Pallis, G. Sfakiotaki, D. Papadatos-Pastos, L. Kalmanti, M. Kafousi, E. Stathopoulos, et al.
Clinical relevance of circulating CK-19 mRNA-positive cells detected during the adjuvant tamoxifen treatment in patients with early breast cancer
Ann. Onc., October 1, 2007; 18(10): 1623 - 1631.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
S Apostolaki, M Perraki, A Pallis, V Bozionelou, S Agelaki, P Kanellou, A Kotsakis, E Politaki, K Kalbakis, A Kalykaki, et al.
Circulating HER2 mRNA-positive cells in the peripheral blood of patients with stage I and II breast cancer after the administration of adjuvant chemotherapy: evaluation of their clinical relevance
Ann. Onc., May 1, 2007; 18(5): 851 - 858.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
N. Xenidis, M. Perraki, M. Kafousi, S. Apostolaki, I. Bolonaki, A. Stathopoulou, K. Kalbakis, N. Androulakis, C. Kouroussis, T. Pallis, et al.
Predictive and Prognostic Value of Peripheral Blood Cytokeratin-19 mRNA-Positive Cells Detected by Real-Time Polymerase Chain Reaction in Node-Negative Breast Cancer Patients
J. Clin. Oncol., August 10, 2006; 24(23): 3756 - 3762.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. Quintela-Fandino, J. M. Lopez, R. Hitt, S. Gamarra, A. Jimeno, R. Ayala, J. Hornedo, C. Guzman, F. Gilsanz, and H. Cortes-Funes
Breast Cancer-Specific mRNA Transcripts Presence in Peripheral Blood After Adjuvant Chemotherapy Predicts Poor Survival Among High-Risk Breast Cancer Patients Treated With High-Dose Chemotherapy With Peripheral Blood Stem Cell Support
J. Clin. Oncol., August 1, 2006; 24(22): 3611 - 3618.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
P. Wulfing, J. Borchard, H. Buerger, S. Heidl, K. S. Zanker, L. Kiesel, and B. Brandt
HER2-Positive Circulating Tumor Cells Indicate Poor Clinical Outcome in Stage I to III Breast Cancer Patients.
Clin. Cancer Res., March 15, 2006; 12(6): 1715 - 1720.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
L. Gao, H. Deng, H. Zhao, A. Hirbe, J. Harding, L. Ratner, and K. Weilbaecher
HTLV-1 Tax transgenic mice develop spontaneous osteolytic bone metastases prevented by osteoclast inhibition
Blood, December 15, 2005; 106(13): 4294 - 4302.
[Abstract] [Full Text] [PDF]


Home page
J. Mol. Diagn.Home page
N. Dandachi, M. Balic, S. Stanzer, M. Halm, M. Resel, T. A. Hinterleitner, H. Samonigg, and T. Bauernhofer
Critical Evaluation of Real-Time Reverse Transcriptase-Polymerase Chain Reaction for the Quantitative Detection of Cytokeratin 20 mRNA in Colorectal Cancer Patients
J. Mol. Diagn., November 1, 2005; 7(5): 631 - 637.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
S. Braun, F. D. Vogl, B. Naume, W. Janni, M. P. Osborne, R. C. Coombes, G. Schlimok, I. J. Diel, B. Gerber, G. Gebauer, et al.
A Pooled Analysis of Bone Marrow Micrometastasis in Breast Cancer
N. Engl. J. Med., August 25, 2005; 353(8): 793 - 802.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. Chavez-MacGregor, A. Aviles-Salas, D. Green, A. Fuentes-Alburo, C. Gomez-Ruiz, and A. Aguayo
Angiogenesis in the Bone Marrow of Patients with Breast Cancer
Clin. Cancer Res., August 1, 2005; 11(15): 5396 - 5400.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
W. Janni, B. Rack, K. Lindemann, and N. Harbeck
Detection of Micrometastatic Disease in Bone Marrow: Is It Ready for Prime Time?
Oncologist, August 1, 2005; 10(7): 480 - 492.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
S. Braun and B. Naume
Circulating and Disseminated Tumor Cells
J. Clin. Oncol., March 10, 2005; 23(8): 1623 - 1626.
[Full Text] [PDF]


Home page
Ann OncolHome page
E. N. Stathopoulos, E. Sanidas, M. Kafousi, D. Mavroudis, J. Askoxylakis, V. Bozionelou, M. Perraki, D. Tsiftsis, and V. Georgoulias
Detection of CK-19 mRNA-positive cells in the peripheral blood of breast cancer patients with histologically and immunohistochemically negative axillary lymph nodes
Ann. Onc., February 1, 2005; 16(2): 240 - 246.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
G. M. Spence, A. N. J. Graham, K. Mulholland, P. Maxwell, W. G. McCluggage, J. M. Sloan, and J. A. McGuigan
Bone Marrow Micrometastases and Markers of Angiogenesis in Esophageal Cancer
Ann. Thorac. Surg., December 1, 2004; 78(6): 1944 - 1949.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
A. Schneeweiss, I. Diel, M. Hensel, S. Kaul, H.-P. Sinn, K. Unnebrink, C. Rudlowski, I. Lauschner, F. Schuetz, G. Egerer, et al.
Micrometastatic bone marrow cells at diagnosis have no impact on survival of primary breast cancer patients with extensive axillary lymph node involvement treated with stem cell-supported high-dose chemotherapy
Ann. Onc., November 1, 2004; 15(11): 1627 - 1632.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
P. F. Ferrucci, C. Rabascio, C. Mazzetta, E. Cocorocchio, A. Agazzi, A. Vanazzi, S. Cinieri, F. A. Peccatori, M. Paolucci, F. Bertolini, et al.
Mammaglobin Expression in Leukapheresis Products Is a Predictive Marker of Poor Prognosis in Women with High-Risk Breast Cancer
Clin. Cancer Res., September 15, 2004; 10(18): 6039 - 6046.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
G. Wiedswang, E. Borgen, R. Karesen, H. Qvist, J. Janbu, G. Kvalheim, J. M. Nesland, and B. Naume
Isolated Tumor Cells in Bone Marrow Three Years after Diagnosis in Disease-Free Breast Cancer Patients Predict Unfavorable Clinical Outcome1
Clin. Cancer Res., August 15, 2004; 10(16): 5342 - 5348.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S.-K. Kraeft, A. Ladanyi, K. Galiger, A. Herlitz, A. C. Sher, D. E. Bergsrud, G. Even, S. Brunelle, L. Harris, R. Salgia, et al.
Reliable and Sensitive Identification of Occult Tumor Cells Using the Improved Rare Event Imaging System
Clin. Cancer Res., May 1, 2004; 10(9): 3020 - 3028.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
B. Naume, G. Wiedswang, E. Borgen, G. Kvalheim, R. Karesen, H. Qvist, J. Janbu, T. Harbitz, and J. M. Nesland
The Prognostic Value of Isolated Tumor Cells in Bone Marrow in Breast Cancer Patients: Evaluation of Morphological Categories and the Number of Clinically Significant Cells
Clin. Cancer Res., May 1, 2004; 10(9): 3091 - 3097.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J.-Y. Pierga, C. Bonneton, A. Vincent-Salomon, P. de Cremoux, C. Nos, N. Blin, P. Pouillart, J.-P. Thiery, and H. Magdelenat
Clinical Significance of Immunocytochemical Detection of Tumor Cells Using Digital Microscopy in Peripheral Blood and Bone Marrow of Breast Cancer Patients
Clin. Cancer Res., February 15, 2004; 10(4): 1392 - 1400.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
K. Pantel, V. Muller, M. Auer, N. Nusser, N. Harbeck, and S. Braun
Detection and Clinical Implications of Early Systemic Tumor Cell Dissemination in Breast Cancer
Clin. Cancer Res., December 15, 2003; 9(17): 6326 - 6334.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
G. Wiedswang, E. Borgen, R. Karesen, G. Kvalheim, J.M. Nesland, H. Qvist, E. Schlichting, T. Sauer, J. Janbu, T. Harbitz, et al.
Detection of Isolated Tumor Cells in Bone Marrow Is an Independent Prognostic Factor in Breast Cancer
J. Clin. Oncol., September 15, 2003; 21(18): 3469 - 3478.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
M. S. Ismail, W. Wynendaele, J. L. E. Aerts, R. Paridaens, L. Van Mellaert, J. Anne, R. Gaafar, N. Shakankiry, H. M. Khaled, M. R. Christiaens, et al.
Real-time quantitative RT-PCR and detection of tumour cell dissemination in breast cancer patients: plasmid versus cell line dilutions
Ann. Onc., August 1, 2003; 14(8): 1241 - 1245.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
T. G. Lugo, S. Braun, R. J. Cote, K. Pantel, and V. Rusch
Detection and Measurement of Occult Disease for the Prognosis of Solid Tumors
J. Clin. Oncol., July 1, 2003; 21(13): 2609 - 2615.
[Full Text] [PDF]


Home page
Ann OncolHome page
N. Xenidis, I. Vlachonikolis, D. Mavroudis, M. Perraki, A. Stathopoulou, N. Malamos, C. Kouroussis, S. Kakolyris, S. Apostolaki, N. Vardakis, et al.
Peripheral blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with operable breast cancer
Ann. Onc., June 1, 2003; 14(6): 849 - 855.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
B. Taback, A. E. Giuliano, N. M. Hansen, F. R. Singer, S. Shu, and D. S. B. Hoon
Detection of Tumor-Specific Genetic Alterations in Bone Marrow from Early-Stage Breast Cancer Patients
Cancer Res., April 15, 2003; 63(8): 1884 - 1887.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
E.-F. Solomayer, M. Feuerer, L. Bai, V. Umansky, P. Beckhove, G. C. Meyberg, G. Bastert, V. Schirrmacher, and I. J. Diel
Influence of Adjuvant Hormone Therapy and Chemotherapy on the Immune System Analysed in the Bone Marrow of Patients with Breast Cancer
Clin. Cancer Res., January 1, 2003; 9(1): 174 - 180.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
A. Stathopoulou, I. Vlachonikolis, D. Mavroudis, M. Perraki, Ch. Kouroussis, S. Apostolaki, N. Malamos, S. Kakolyris, A. Kotsakis, N. Xenidis, et al.
Molecular Detection of Cytokeratin-19-Positive Cells in the Peripheral Blood of Patients With Operable Breast Cancer: Evaluation of Their Prognostic Significance
J. Clin. Oncol., August 15, 2002; 20(16): 3404 - 3412.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
E. M. Kirchner, R. Gerhards, and R. Voigtmann
Sequential immunochemotherapy and edrecolomab in the adjuvant therapy of breast cancer: reduction of 17-1A-positive disseminated tumour cells
Ann. Onc., July 1, 2002; 13(7): 1044 - 1048.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
A. L. Silva, M. J. Tome, A. E. Correia, and J. L. Passos-Coelho
Human mammaglobin RT-PCR assay for detection of occult breast cancer cells in hematopoietic products
Ann. Onc., March 1, 2002; 13(3): 422 - 429.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
E.-F. Solomayer, I. J. Diel, G. Salanti, M. Hahn, C. Gollan, F. Schutz, and G. Bastert
Time Independence of the Prognostic Impact of Tumor Cell Detection in the Bone Marrow of Primary Breast Cancer Patients
Clin. Cancer Res., December 1, 2001; 7(12): 4102 - 4108.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
B. Naume, E. Borgen, G. Kvalheim, R. Karesen, H. Qvist, T. Sauer, T. Kumar, and J. M. Nesland
Detection of Isolated Tumor Cells in Bone Marrow in Early-Stage Breast Carcinoma Patients: Comparison with Preoperative Clinical Parameters and Primary Tumor Characteristics
Clin. Cancer Res., December 1, 2001; 7(12): 4122 - 4129.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
G. Gebauer, T. Fehm, E. Merkle, E. P. Beck, N. Lang, and W. Jager
Epithelial Cells in Bone Marrow of Breast Cancer Patients at Time of Primary Surgery: Clinical Outcome During Long-Term Follow-Up
J. Clin. Oncol., August 15, 2001; 19(16): 3669 - 3674.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
G. Mehes, A. Witt, E. Kubista, and P. F. Ambros
Circulating Breast Cancer Cells Are Frequently Apoptotic
Am. J. Pathol., July 1, 2001; 159(1): 17 - 20.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
C. Bokemeyer, A. J.M. Gillis, K. Pompe, F. Mayer, B. Metzner, N. Schleucher, J. Schleicher, G. Pflugrad-Jauch, J. W. Oosterhuis, L. Kanz, et al.
Clinical Impact of Germ Cell Tumor Cells in Apheresis Products of Patients Receiving High-Dose Chemotherapy
J. Clin. Oncol., June 15, 2001; 19(12): 3029 - 3036.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. Kasimir-Bauer, S. Mayer, P. Bojko, D. Borquez, R. Neumann, and S. Seeber
Survival of Tumor Cells in Stem Cell Preparations and Bone Marrow of Patients with High-Risk or Metastatic Breast Cancer after Receiving Dose-intensive or High-Dose Chemotherapy
Clin. Cancer Res., June 1, 2001; 7(6): 1582 - 1589.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
I. Y. Cheung and N.-K. V. Cheung
Quantitation of Marrow Disease in Neuroblastoma by Real-Time Reverse Transcription-PCR
Clin. Cancer Res., June 1, 2001; 7(6): 1698 - 1705.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Wu, A. Mazumder, R. L. Martuza, X. Liu, M. Thein, K. R. Meehan, and S. D. Rabkin
Biological Purging of Breast Cancer Cells Using an Attenuated Replication-competent Herpes Simplex Virus in Human Hematopoietic Stem Cell Transplantation
Cancer Res., April 1, 2001; 61(7): 3009 - 3015.
[Abstract] [Full Text]


Home page
The OncologistHome page
S. Braun and K. Pantel
Clinical Significance of Occult Metastatic Cells in Bone Marrow of Breast Cancer Patients
Oncologist, April 1, 2001; 6(2): 125 - 132.
[Abstract] [Full Text]


Home page
JCOHome page
S. Braun, B. S. Cevatli, C. Assemi, W. Janni, C. R.M. Kentenich, C. Schindlbeck, D. Rjosk, and F. Hepp
Comparative Analysis of Micrometastasis to the Bone Marrow and Lymph Nodes of Node-Negative Breast Cancer Patients Receiving No Adjuvant Therapy
J. Clin. Oncol., March 1, 2001; 19(5): 1468 - 1475.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
B. Gerber, A. Krause, H. Muller, D. Richter, T. Reimer, J. Makovitzky, C. Herrnring, U. Jeschke, G. Kundt, and K. Friese
Simultaneous Immunohistochemical Detection of Tumor Cells in Lymph Nodes and Bone Marrow Aspirates in Breast Cancer and Its Correlation With Other Prognostic Factors
J. Clin. Oncol., February 15, 2001; 19(4): 960 - 971.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
K. D. Bauer, Jose de la Torre-Bueno, I. J. Diel, D. Hawes, W. J. Decker, C. Priddy, B. Bossy, S. Ludmann, K. Yamamoto, A. S. Masih, et al.
Reliable and Sensitive Analysis of Occult Bone Marrow Metastases Using Automated Cellular Imaging
Clin. Cancer Res., September 1, 2000; 6(9): 3552 - 3559.
[Abstract] [Full Text]


Home page
NEJMHome page
S. Braun, K. Pantel, P. Muller, W. Janni, F. Hepp, C. R.M. Kentenich, S. Gastroph, A. Wischnik, T. Dimpfl, G. Kindermann, et al.
Cytokeratin-Positive Cells in the Bone Marrow and Survival of Patients with Stage I, II, or III Breast Cancer
N. Engl. J. Med., February 24, 2000; 342(8): 525 - 533.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
S. von Mensdorff-Pouilly, A. A. Verstraeten, P. Kenemans, F. G. M. Snijdewint, A. Kok, G. J. Van Kamp, M. A. Paul, P. J. Van Diest, S. Meijer, and J. Hilgers
Survival in Early Breast Cancer Patients Is Favorably Influenced by a Natural Humoral Immune Response to Polymorphic Epithelial Mucin
J. Clin. Oncol., February 1, 2000; 18(3): 574 - 574.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
S. Braun, C. Kentenich, W. Janni, F. Hepp, J. de Waal, F. Willgeroth, H. Sommer, and K. Pantel
Lack of Effect of Adjuvant Chemotherapy on the Elimination of Single Dormant Tumor Cells in Bone Marrow of High-Risk Breast Cancer Patients
J. Clin. Oncol., January 5, 2000; 18(1): 80 - 80.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
D. Weckermann, P. Muller, F. Wawroschek, G. Krawczak, G. Riethmuller, and G. Schlimok
Micrometastases of Bone Marrow in Localized Prostate Cancer: Correlation With Established Risk Factors
J. Clin. Oncol., November 1, 1999; 17(11): 3438 - 3443.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
K. Pantel, R. J. Cote, and O. Fodstad
Detection and Clinical Importance of Micrometastatic Disease
J Natl Cancer Inst, July 7, 1999; 91(13): 1113 - 1124.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
S. Offner, W. Schmaus, K. Witter, G. B. Baretton, G. Schlimok, B. Passlick, G. Riethmuller, and K. Pantel
p53 gene mutations are not required for early dissemination of cancer cells
PNAS, June 8, 1999; 96(12): 6942 - 6946.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. Mohr, E. Hilgenfeld, T. Fietz, B. Hoppe, M. Koenigsmann, M. Hoffmann, W. U. Knauf, U. Cassens, W. Sibrowski, J. Kienast, et al.
Efficacy and Safety of Simultaneous Immunomagnetic CD34+ Cell Selection and Breast Cancer Cell Purging in Peripheral Blood Progenitor Cell Samples Used for Hematopoietic Rescue after High-Dose Therapy
Clin. Cancer Res., May 1, 1999; 5(5): 1035 - 1040.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
I. Vogel, U. Kruger, J. Marxsen, E. Soeth, H. Kalthoff, D. Henne-Bruns, B. Kremer, and H. Juhl
Disseminated Tumor Cells in Pancreatic Cancer Patients Detected by Immunocytology: A New Prognostic Factor
Clin. Cancer Res., March 1, 1999; 5(3): 593 - 599.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
E. Putz, K. Witter, S. Offner, P. Stosiek, A. Zippelius, J. Johnson, R. Zahn, G. Riethmuller, and K. Pantel
Phenotypic Characteristics of Cell Lines Derived from Disseminated Cancer Cells in Bone Marrow of Patients with Solid Epithelial Tumors: Establishment of Working Models for Human Micrometastases
Cancer Res., January 1, 1999; 59(1): 241 - 248.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
M. Meli, L. Rausa, L. C. Panasci, V. Sandor, D. Melnychuk, C. D. Atkins, I. J. Diel, S. D. Costa, and M. Kaufmann
Clodronate in Metastatic Breast Cancer
N. Engl. J. Med., December 24, 1998; 339(26): 1940 - 1941.
[Full Text]


Home page
NEJMHome page
I. J. Diel, E.-F. Solomayer, S. D. Costa, C. Gollan, R. Goerner, D. Wallwiener, M. Kaufmann, and G. Bastert
Reduction in New Metastases in Breast Cancer with Adjuvant Clodronate Treatment
N. Engl. J. Med., August 6, 1998; 339(6): 357 - 363.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.